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Summary
A literature review of the treatment of cartilage defects was conducted, examining the current 
literature on the well-known treatments. In particular, advantages and drawbacks of each of the 
discussed treatments were evaluated considering outcomes available in literature. The literature 
search was conducted on PubMed and Scopus using appropriate keywords in relation to carti-
lage defects. Main research articles were selected for review.
Cartilage damage affects thousands of persons each year; they are treated with implants and 
surgery. A major problem in the treatment of cartilage defects is the inability of cartilage to 
repair, which reduces the effectiveness of the treatment. In addition, cyclic loading of joints fur-
ther degrades cartilage even after treatment. In relation to the conditions of cartilage lesions 
and the features of patients, a specific treatment is required in each case. Current treatments are 
often unpredictable in results but result in long term improvements for many patients, espe-
cially young patients.
The well established treatments such as osteochondral implants, bone marrow stimulation tech-
niques, chondrogenic cell implantations have advantages and drawbacks, so that the search has 
not been interrupted for new strategies, such as scaffold materials. In this review we describe 
benefits and disadvantages of the established methods of cartilage regeneration that seem to 
have a better long-term effectiveness.
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Introduction
Hyaline cartilage covers the opposing osseous ends of every diarthrodial human 
joint (Pichler et al., 2013; Cardile et al., 2013). Many joints may be affected by osteoar-
thritis (OA), which represents a major health problem. In the knees, one of the protec-
tion mechanisms against cartilage wear comes from the presence of the two menisci 
(Loreto et al., 2012; Musumeci et al., 2012, 2013a, 2013b). To protect the underlying 
bone, articular cartilage allows a continuous and almost frictionless movement of 
the bony skeleton over years (Musumeci et al., 2011a, 2013c). Mature human chon-
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drocytes, located in lacunae within the matrix, represent only 5% to 10% of the total 
cartilage volume but are crucial to the maintenance of a stable extra-cellular matrix 
(ECM). Chondrocytes are responsible for anabolic and catabolic conversion of the 
ECM macromolecules (Loreto et al., 2011). The two main ECM components are type 
II collagen and large chondroitin sulfate proteoglycan aggregates. Type II colla-
gen primarily endows the cartilage with its tensile strength, whereas aggrecan pro-
vides the osmotic resistance for cartilage to withstand compressive loads (Loreto et 
al., 2011). Without any neural, lymphatic or vascular supply, cartilage resists heavy 
mechanical load over years without degenerative changes. Due to its unique proper-
ties, cartilage shows little or no intrinsic capacity for an effective healing response. 
At most a fibrocartilaginous scar results in response to trauma. Major expression of 
type I collagen and too small amounts of aggrecan leads to a poor quality repair tis-
sue that does not resist the common mechanical forces within the joint. The chondral 
defect results in a progressive degeneration and damage, which may lead to an early 
onset of osteoarthritis (Buckwalter, 2002; Musumeci et al., 2011b). The aim of any car-
tilage repair procedure is to restore the defect with an optimal repair tissue, mechani-
cally stable, in order to prevent further degeneration.
Currently, there are three different clinical methods available for repairing a chon-
dral defect: penetration of the subchondral bone, osteochondral plug transplantation 
and chondrocyte transplantation. None of the mentioned procedures is capable to gen-
erate hyaline cartilage and the clinical outcome needs to be further improved. Small 
sized articular lesions are commonly addressed arthroscopically by penetration of the 
underlying subchondral bone (Steadman et al., 2001) to promote a fibrous scar within 
the defect by invasion of adult mesenchymal stem cells (MSC). However, the reparative 
tissue does not withstand repetitive mechanical forces becsause of its poor quality, con-
sisting mainly of collagen type I, and the clinical outcome deteriorates over time (Kreuz 
et al., 2006). Osteochondral plug transplantation, or ostechondral autograft transfer sys-
tem (OATS), usually applied for mid-sized defects (Hangody and Fules, 2003), imme-
diately recovers the joint surface. Pioneered by the work of Brittberg in 1994, cell-based 
treatment methods for repairing particularly large chondral lesions across the knee joint 
have been developed (Brittberg et al., 1994). Most articular cartilage tissue engineer-
ing approaches include the use of transplanted cells due to the low metabolic rate of 
native, mature chondrocytes. Traditionally, autologous articular chondrocytes are used 
(Brittberg et al., 1994), but allogenic chondrocytes (Dhollander et al., 2012), chondro-
cytes from other cartilaginous tissues, and chondroprogenitor cells have also been used 
(Klein-Nulend et al., 1998). Chondrocyte transplantation is one of the most success-
ful techniques used to treat cartilage defects in humans (Peterson et al., 2003), though 
implanted grafts do not provide primary mechanical stability and various side effects, 
leading to procedure failure, have been reported (Knutsen et al., 2004; Wood et al., 
2006). In this review we describe benefits and disadvantages of the established methods 
of cartilage regeneration that seem to have a better long-term effectiveness.
Osteochondral implants
Osteochondral implants are procedures of autologous osteochondral transplanta-
tion that involve transplantation of small cylindrical autologous osteochondral grafts 
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harvested from the articular surface and transferred to create a resurfaced area in the 
lesion. This technique offers some advantages including transplantation of hyaline 
cartilage and a brief rehabilitation period, furthermore the procedure requires only 
a single intervention. The limitations of this technique include donor site morbid-
ity, a limited availability of grafts that can be harvested, the absence of fill and the 
potential dead space between grafts that may limit the quality of the repair. Site heal-
ing results in filling of the lesion with cancellous bone and a fibrocartilage-like cap. 
It seems that large grafts determine greater morbidity and therefore it is suggested 
to use small grafts and fill the lesion with biocompatible material that may help to 
prevent morbidity (Bedi et al., 2010). Hydroxyapatite, carbon fiber, polyglyconate B, 
compressed collagen, and polycaprolactones have been used in a canine model to 
estimate healing of site lesions (Feczko et al., 2003). All these biocompatible materi-
als show a good integration with the surrounding cancellous bone, but compressed 
collagen shows the most favorable fibrocartilage covering. However, osteochondral 
implants are controversial procedures in relation to the possible and uncertain effects 
of high nanoparticle concentrations of biocompatible materials in the bloodstream. 
Despite this, the outcomes of autologous osteochondral transplantation are encour-
aging. Several authors have evaluated the technique performed for femoral, tibial, 
patellar chondral lesions and for osteochondritis dissecans lesions; they have report-
ed up to 92% rate of good-to-excellent results after a period of follow-up of several 
months, a 3% rate of donor site morbidity and the magnetic resonance imaging per-
formed at the time of final follow-up has revealed nearly complete fill in all plugs 
(Hangody and Fules, 2003; Ozturk et al., 2006; Miniaci and Tytherleigh-Strong, 2007; 
Hangody et al., 2008; Nho et al., 2008; Widuchowski et al., 2008).
An alternative technique of osteochondral implants is the osteochondral allograft 
transplantation. It involves graft transplantation of intact articular cartilage from 
cadaver into the lesion. Advantages of this procedure are to achieve precise surface 
architecture, immediate transplantation of hyaline cartilage as a single-stage proce-
dure, the potential to replace large lesions, and no donor site morbidity (Bedi et al., 
2010). Limitations are limited graft availability, high cost, risk of immunological rejec-
tion, possible incomplete graft incorporation, potential for disease transmission, and 
the technically demanding aspects of machining and sizing of the allograft (Bedi et 
al., 2010). In osteochondral allograft transplantation it is possible to use three kinds of 
grafts: fresh allografts, cryopreserved allografts, fresh-frozen allografts. Fresh osteo-
chondral allografts are preferred because both freezing and cryopreservation decrease 
chondrocyte viability. Chondrocyte function maintains the dynamic homeostasis of 
the extracellular matrix and it is important to ensure long-term allograft survival in 
vivo (Bakay et al., 1998). Fresh osteochondral allografts, stored in Ringer solution at 
4°C, are transplanted within one week.  The rate of chondrocyte viability upon allo-
graft storage in culture medium is higher (91%) than upon storage in lactate-Ringer 
solution (80%; Ball et al., 2004). The matrix properties and chondrocyte viability of 
stored fresh osteochondral allografts have been evaluated and although the biome-
chanical properties and matrix integrity of hyaline cartilage are preserved for up to 
twenty-eight days, the number of viable chondrocytes has been shown to decrease 
progressively over that time (Pearsall et al., 2004; Allen et al., 2005). Hyaline cartilage 
is an immune-privileged tissue because of its avascular matrix that preserves chon-
drocytes from the host immune reaction. The allograft bone is necrotic but it provides 
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a structural scaffold to support the articular surface during this gradual incorpora-
tion. Cryopreservation of allografts involves freezing of grafts in a nutrient-rich medi-
um with cryoprotectants such as glycerol or dimethyl sulfoxide to minimize cellular 
freezing and maintain cell viability. A 77% rate of chondrocyte viability at one year 
has been reported for cryopreserved osteochondral allografts implanted into load-
bearing sites in an animal model (Gole et al., 2004). Another study has demonstrated, 
at five years, degenerative changes at the articular surface of cryopreserved allografts 
compared with fresh allografts (Bakay et al., 1998). Cryopreserved allografts achieve 
better results compared with fresh allografts (Schachar et al., 1999). Fresh-frozen pres-
ervation of allografts has the advantages of reduced immunogenicity and decreased 
disease transmission but is hampered by lower chondrocyte viability. The process 
of deep-freezing to 280°C destroys the viability of articular cartilage cells within the 
grafts and studies have demonstrated deterioration of cells and matrix (Gole et al., 
2004). Several studies have been performed to assess the outcome of osteochondral 
allograft transplantation and they report good-to-excellent results in up to 86% cases 
even after many years from transplantation (Bugbee and Convery, 1999; Chu et al., 
1999; Davidson et al., 2007). Overall, the best results with allograft transplantation 
have been reported for the treatment of osteochondritis dissecans lesions of the knee 
(Emmerson et al., 2007). The outcome is less reliable and predictable in primary oste-
oarthritis, inflammatory arthropathy, limb malalignment, bipolar lesions of the knee 
and patella-femoral chondral lesions (Jamali et al., 2005).
Bone Marrow Stimulation
Bone marrow stimulation techniques are the most widely used methods for the 
treatment of symptomatic small lesions of articular cartilage. Microfracture surgery is 
performed according to the method described by Steadman (Steadman et al., 2001). 
This technique uses an awl to perform microfractures into the intracortical bone. 
Neighboring mesenchymal stem cells leak into these holes and form a combination 
of cartilage and fibrous tissue with varying amounts of type-II collagen content (Fris-
bie et al., 2003; Steadman et al., 2003; Knutsen et al., 2004; Gobbi et al., 2005). The 
total concentration of mesenchymal stem cells is rather low and decreases with age 
(Tran-Khanh et al., 2005). The formation of a stable blood clot that fills the lesion is 
important, and it has been correlated with the success of the microfracture surgery 
technique, therefore unstable clots that are only partially adherent or fill only a por-
tion of the lesion will repair in a suboptimal manner (Frisbie et al., 2003). The crea-
tion of a restricted lesion bordered by healthy cartilage is essential for obtaining an 
optimal filling of the lesion with a clot and the adhesion of this one (Mithoefer et al., 
2006; Asik et al., 2008). The layer of calcified cartilage underlying the lesion must be 
removed to ensure the adhesion of the clot (Frisbie et al., 2006). The postoperative 
scheme is important for an optimal result of the microfracture surgery (Steadman et 
al., 2007), it consists of a continuous passive motion, 6-8 hours a day, for six weeks 
(Steadman et al., 2003; Gill et al., 2006). Data show that microscopic examination 
of the mandibular condylar cartilage of the animals placed on continuous passive 
motion showed a marked increase in thickness compared with the condylar cartilage 
found on the control animals, because of stimulation of the mesenchymal stem cells 
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to differentiate (Mussa et al., 1999). Unlimited movement is normally allowed after 
two months and a return to full activity is allowed after three months (Steadman et 
al., 2003; Gill et al., 2006).
The overall clinical results with microfracture surgery show improved articular 
function in 70% to 95% of patients, and most of the improvement has been shown 
in the first two postoperative years while deterioration of articular has been detect-
ed function after two years; the reason for this deterioration has not yet been iden-
tified (Steadman et al., 2003; Knutsen et al., 2004; Gobbi et al., 2005). Some studies 
provide clinical evidence that repair cartilage volume plays a critical role in the dura-
bility of functional improvement in the knee after microfracture surgery. Results of 
these studies highlight that there are patients who do not form a sufficient amount 
of repair cartilage after microfracture surgery and they have only a temporary func-
tional improvement, in contrast with patients with a high fill volume that have supe-
rior functional results and durability (Mithoefer et al., 2005). Data indicate that dete-
rioration of knee function is not limited to patients with a poor fill grade and that 
other factors should be considered such as age and body-mass index. Some authors 
show that a lower body-mass index is correlated with better results; it seems that an 
excessive body-mass index is a contraindication for microfracture surgery in the knee 
(Mithoefer et al., 2005; Mithoefer et al., 2006). Other authors argue that the age is an 
independent predictor of functional improvement; their studies show that articular 
cartilage repair after microfracture surgery in patients who are less than thirty years 
old have better clinical outcomes (Steadman et al., 2003; Knutsen et al., 2004). A better 
functional result in patients younger than thirty years may be attributed to an age-
dependent qualitative and quantitative difference in metabolic activity in the repaired 
cartilage (Martin and Buckwalter, 2003). Cartilage lesions untreated for prolonged 
periods may lead to the development of early degenerative joint changes, particularly 
at the margin of the lesions, explaining the worse results with late repair observed 
in some investigations. Some authors emphasize the importance of early surgical 
treatment of articular cartilage lesions (Mithoefer et al., 2005). In summary, microfrac-
ture surgery provides subjective functional improvement and significantly increased 
activity levels in patients with isolated articular cartilage lesions. The best functional 
results are observed in patients with a good volume of repair cartilage, a lower body-
mass index and a shorter preoperative duration of symptoms. The drawback of this 
procedure is the high probability of recurrence of symptoms after one to two years 
(Negrin et al., 2012).
Procedures to improve the stability of the clot and the filling of the lesion have 
been described. In an ovine model, stabilization of the blood clot by the addition of 
chitosan, an adhesive and thrombogenic polymer, resulted in a better filling of the 
lesion and tissue healing after microfracture surgery (Hoemann et al., 2005). Growth 
factors have been used for cartilage repair in vivo, so insulin-like growth factor has 
improved both quantity and quality of cartilage tissue repair and has reduced the 
severity of postoperative inflammation in an equine model (Nixon et al., 2005). Plate-
let-derived growth factor is a potent mitogen for mesenchymal cells; some studies 
have shown promising results in relation to its ability to stimulate the formation of 
hyaline cartilage and the proliferation of chondrocytes (Akeda et al., 2006; Mishra et 
al., 2009). Finally, Strauss et al. evaluated the results of microfracture surgery with or 
without hyaluronic acid supplement in a New Zealand white rabbit model (Strauss et 
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al., 2009). After three months from microfracture surgery, the histological examination 
of tissue repair has revealed better filling of the lesion and less degenerative changes 
than in controls.
However, none of these adjuvants to microfracture surgery has yet been tested on 
humans, and therefore their clinical efficacy has yet to be tested.
Chondrogeneic cell implantation
Autologous chondrocyte implantation (ACI: Fig. 1) is a procedure that has the aim 
of repairing chondral defects by implanting cartilage cells. There are three genera-
tions of ACI:
1st generation, with a chondrocyte suspension implanted under a periosteal flap;
2nd generation, with a chondrocyte suspension implanted under a collagen mem-
brane;
3rd generation, with cells grown on or in matrices implanted as immature grafts 
into the defects.
The benefit of ACI is the development of hyaline-like cartilage rather than fibro-
cartilage in the lesion, leading to better long-term outcomes. This procedure requires 
that cartilage cells are removed from the injured knee and grown in culture. The cells 
are then implanted into the defect where they grow and fill the lesion regenerating a 
Figure 1 – Diagram of autologous chondrocytes transplantation (ACI).
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cartilage surface (Bedi et al., 2010). Studies on ACI in patients monitored for a long 
period have reported good-to-excellent results based on pain and quality of life, and 
biopsies have shown that the regenerated tissue had the appearance of hyaline car-
tilage (Brittberg et al., 1994; Zaslav et al., 2009). Autologous chondrocyte implanta-
tion has some limitations. The drawbacks of this method are the requirement for two 
surgical interventions, a very slow recovery (12 to 18 months) and a high cost (Britt-
berg et al., 1994). Complications have also been reported (Wood et al., 2006; Bedi et 
al., 2010) as well as adverse events such as periosteal hypertrophy and graft failure 
which may require further operation.
In matrix-associated chondrocyte implantation the cells are included into a por-
cine type I/III collagen membrane. This membrane has large interstices between fib-
ers, where chondrocytes settle and proliferate. This procedure minimizes donor site 
morbidity, prevents dedifferentiation of chondrocytes during culture and may be per-
formed at arthroscopy (Bedi et al., 2010). Using  fibrin glue as matrix, a completely 
attached graft has been observed in 88% patients (Marlovits et al., 2005). The efficacy 
of matrix-associated chondrocyte implantation has been also evaluated in an ovine 
model; magnetic resonance imaging has shown that matrix associated chondrocyte 
implantation is superior to lack of treatment (Dorotka et al., 2005; Jones et al., 2008). 
Zheng et al. (2007) have analysed chondrocytes seeded on a type I/III collagen scaf-
fold: the cells appeared spherical and integrated into the matrix and expressed type 
II collagen and aggrecan; parallel histological analyses on patients treated by implan-
tation of such cell-bearing scaffolds showed 75% hyaline-like cartilage regeneration 
after six months. Similar studies on patients with a longer follow-up found that the 
repair process progressed to total defect filling with complete integration (Smith et 
al., 2005; Trattnig et al., 2005; Behrens et al., 2006; Wright, 2009). Another procedure 
takes advantage of a ‘‘sandwich’’ technique, by which two matrix membranes are cut 
to the size of the defect and one of them is fixed with fibrin glue to the base of the 
defect itself while the second one is implanted on top of the other and is sealed with 
fibrin glue to the adjacent cartilage. This technique is suitable for deep osteochondral 
defects and is combined with bone filling at the bottom of the defect. In one report, 
all patients had improved function within six months (Bartlett et al., 2005).
Scaffolds analogous to the natural three-dimensional extracellular matrix may pro-
vide important microenvironmental clues to cells. A wide array of materials has been 
used in various in vitro and in vivo studies for articular cartilage engineering. Candi-
date materials must be biocompatible and accommodate cell adhesion, proliferation, 
and matrix synthesis. Scaffolds that are most often studied in cartilage tissue engineer-
ing include hydrogels made from collagen (Dorotka et al., 2005), fibrin (Peretti et al., 
2000; Ameer et al., 2002), agarose, and synthetic peptides (Kisiday et al., 2002; Kisi-
day et al., 2004); sponge-like scaffolds manufactured from materials such as collagen, 
polyglycolic acid, polylactic acid (Grande et al., 1997), and polyurethane (Grad et al., 
2005; Gogolewski et al., 2008); materials with a naturally-occurring porous structure, 
such as coral, devitalized articular cartilage (Hangody et al., 2008) and hyaluronan-
based scaffolds (Kang et al., 2009). Hyaluronan-based scaffolds provide the autologous 
chondrocytes a scaffold of hyaluronan derivatives. This is a procedure for cartilage 
repairing that employs a biodegradable, three-dimensional scaffold for cell prolifera-
tion. A benzylic ester of hyaluronic acid is used to generate a scaffold with variably 
sized interstices between 20 mm thick fibers. The three-dimensional scaffold provides 
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the structural support for cell contact and matrix deposition prevents dedifferentiation 
of autologous chondrocytes even after long periods and promotes the expression of 
chondrocyte-specific markers (Filova et al., 2008). Advantages of this procedure are 
a more uniform cell distribution, avoidance of periosteal harvest and implantation, 
and increased technical ease without the need for suturing to adjacent articular carti-
lage. Histological analysis of implantation of hyaluronan-based scaffolds seeded with 
autologous chondrocytes shows hyaline-like cartilage in the lesion as soon as twelve 
months after implantation. Marcacci et al. (2005) have reported the outcome of hyalu-
ronan-based scaffold in patients with a chondral defect; after a period of thirty-eight 
months following treatment, 92% patients had improved their function and arthro-
scopic evaluation revealed complete coverage of the defect with a hyaline-like repara-
tive tissue. In another study the hyaluronan-based scaffolds seeded with autologous 
chondrocytes has been evaluated as a treatment for patello-femoral chondral lesions; 
magnetic resonance imaging at twenty-four months has revealed that 71% cases has 
complete filling and absence of subchondral edema, with a positive correlation with 
clinical outcome; arthroscopy revealed complete filling of the defects with reparative 
tissue that was characterized as hyaline-like histologically (Gobbi et al., 2006). Nowa-
days the techniques of tissue engineering have progressed further and, for example, 
they can provide collagen matrices seeded with chondrocytes. Autologous chondro-
cytes are harvested in a manner analogous to conventional autologous chondrocyte 
implantation. The cells are then included in a type-I bovine collagen matrix and cul-
tured ex vivo. The cell-scaffold construct is subjected to mechanical stimulation with 
use of hydrostatic pressure, because the application of mechanical load stimulates 
chondrocytes to produce increased amounts of type-II collagen, aggrecan, and other 
components of the hyaline extracellular matrix (Bedi et al., 2010). The cell-scaffold 
construct is then fixed to the patient with a collagen bioadhesive, which is applied to 
the base of the defect (Ryan et al., 2009). The clinical outcome associated to date with 
tissue-engineered collagen matrices seeded with autologous chondrocytes show good 
long-term results in several cases of matrix associated ACI.
Crawford et al. (2009) reported the results of a clinical trial on eight patients with 
twenty-four months of follow-up. Magnetic resonance imaging showed that seven of 
the eight patients had complete or nearly complete filling of the defect at one year, 
and six of the eight maintained good filling at two years.
In procedures of cartilage regeneration that require an expansion of stem cells 
or chondrocytes, various growth factors, i.e. fibroblast growth factor-2, transform-
ing growth factor-β (TGF- β), insulin-like growth factor-1 and osteogenic protein-1, 
have been used to modulate chondrocyte phenotype, proliferation and biosynthetic 
activity. In particular, chondrogenic medium containing dexamethasone and TGF-β1 
has been developed to induce chondrogenic differentiation from chondroprogenitor 
cells (Johnstone et al., 1998). However, when considering the natural in vivo repair 
environment, it must be also considered what would be the natural source of these 
factors. Li et al. (2009) demonstrated that chondrogenesis can be induced in vitro 
in absence of TGF-β when mechanical load is applied. Under these conditions the 
cells up-regulate the synthesis of TGF-β and this is responsible for the chondrogenic 
response. Thus, in the natural in vivo environment a suitable rehabilitation protocol 




Cartilage damage due to deterioration or autoimmune disorders is generally 
chronic because of the low regenerative ability of cartilage tissue. One of the first, 
but more invasive, clinical cartilage treatments is the joint replacement. This is a pro-
cedure of orthopedic surgery in which the arthritic or dysfunctional joint surface is 
replaced with an orthopedic prosthesis. In this treatment, a highly cross-linked poly-
mer cap connected to metal components is used to replace the function of the natural 
cartilage. However joint replacements have a lifetime of 15-20 years (van Ooij et al., 
2003), and this may be a problem for younger people. This treatment involves sub-
stantial postoperative pain, and it is necessary a vigorous physical rehabilitation. The 
recovery period may be 6 weeks or longer and may involve the use of mobility aids. 
Joint replacement is considered as a treatment when severe joint pain or dysfunctions 
are not alleviated by less-invasive therapies. Because of these reasons, tissue engi-
neering of natural cartilage tissue has become an attractive new area of research. In 
this review, we have described the most widely used techniques in the treatment of 
cartilage lesions to solve the problem of the management of cartilage defects.
Conclusions
In conclusion, the treatment of articular cartilage defects can be approached by 
different procedures in relation to cartilage lesions. Current data suggest that favora-
ble outcomes of microfracture surgery and whole-tissue transplantation of allografts 
or autografts are achieved for the treatment of cartilage defects. Further in vivo and 
in vitro studies must be carried out in order to confirm their successful clinical out-
comes.
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